Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an engineered immune cell therapy can halt the progression of the autoimmune disease.
The University of New Mexico Comprehensive Cancer Center has opened a clinical trial that applies hyperthermic intraperitoneal chemotherapy (HIPEC) — a proven surgical technique that is used in digestive system cancers — to ovarian cancer.
Vanderbilt University Medical Center (VUMC) is one of roughly 60 study sites worldwide participating in RESPONDER-HF, a randomized clinical trial of an atrial shunt to treat heart failure patients.
In an effort to combat one of the most lethal forms of pediatric brain cancer, researchers at the UCLA Health Jonsson Comprehensive Cancer Center are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma, a highly aggressive brain tumor that is typically found in adolescents and young adults.
People with Parkinson’s disease are receiving a new treatment in a clinical trial started after University of Wisconsin–Madison scientists demonstrated the safety and feasibility of the therapeutic delivery method in a study of non-human primates.
Hadas Nahman-Averbuch, PhD, an assistant professor of anesthesiology at Washington University School of Medicine in St. Louis, is leading two studies to help predict who is at risk of developing migraine disorder, and to identify the changes in brain connectivity and hormone levels that precede the onset of migraine headaches in adolescents.
Over $10 million in NIH grants will fund University of Illinois Chicago studies using digital tools to improve mental health
Corewell Health is working with Johns Hopkins Bloomberg School of Public Health and North Carolina Agricultural and Technical State University to learn more about the multi-level risk and biopsychosocial factors that contribute to Alzheimer’s disease in Black Americans, leading to the development of effective, tailored behavioral and pharmacological interventions aimed at reducing the condition’s disparate attack.
The Speech Accessibility Project is partnering with several organizations who serve people with cerebral palsy as it recruits more participants for its speech recognition technology work. They include ADAPT Community Network, the Cerebral Palsy Foundation and CP Unlimited.
In collaboration with the company Pleural Dynamics, researchers at the UNC School of Medicine are the first to use a fully implantable automatic effusion shunt with no external catheters or expensive drainage canisters to provide an innovative new option for patients who struggle with chronic fluid collection.
The UC Davis Department of Obstetrics and Gynecology is recruiting potential participants for a clinical trial of an investigational hormone-free monthly intravaginal method of contraception.
Strong bitterness is the main reason why people all over the world, especially children, avoid taking their medicines, putting their health, and sometimes, their lives at risk. Now, a group of scientists at the Monell Chemical Senses Center identified the first temporary, universal taste blocker that works in people.
Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).
The University of Illinois Chicago study will be the first to assess whether the natural product has anti-cancer effects that could benefit patients as they await surgical treatment.
The Icahn School of Medicine at Mount Sinai Health System is spearheading a collaborative effort to investigate dupilumab as a treatment for children with alopecia areata, a disease that causes extensive hair loss.
The first U.S. heart patient involved in a study for a new gene-editing therapy has successfully been treated at MedStar Washington Hospital Center.
MD Anderson and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for PRAME TCR/IL-15 NK (SY-307), an engineered T cell receptor natural killer (TCR NK) cell therapy for relapsed/refractory myeloid malignancies.
The Speech Accessibility Project, which aims to make automatic speech recognition technology more accessible to people with speech differences and disabilities, is now sharing some of its voice recordings and related data with universities, nonprofits and companies.
A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.
A clinical trial from Keck Medicine of USC aims to provide a surgical solution for patients with a form of advanced pancreatic cancer previously considered inoperable.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right